Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 116(23): 11396-11401, 2019 06 04.
Article in English | MEDLINE | ID: mdl-31097590

ABSTRACT

α-Dystroglycan (α-DG) is a highly glycosylated basement membrane receptor that is cleaved by the proprotein convertase furin, which releases its N-terminal domain (α-DGN). Before cleavage, α-DGN interacts with the glycosyltransferase LARGE1 and initiates functional O-glycosylation of the mucin-like domain of α-DG. Notably, α-DGN has been detected in a wide variety of human bodily fluids, but the physiological significance of secreted α-DGN remains unknown. Here, we show that mice lacking α-DGN exhibit significantly higher viral titers in the lungs after Influenza A virus (IAV) infection (strain A/Puerto Rico/8/1934 H1N1), suggesting an inability to control virus load. Consistent with this, overexpression of α-DGN before infection or intranasal treatment with recombinant α-DGN prior and during infection, significantly reduced IAV titers in the lungs of wild-type mice. Hemagglutination inhibition assays using recombinant α-DGN showed in vitro neutralization of IAV. Collectively, our results support a protective role for α-DGN in IAV proliferation.


Subject(s)
Cell Proliferation/drug effects , Dystroglycans/pharmacology , Influenza A Virus, H1N1 Subtype/drug effects , Protective Agents/pharmacology , Animals , Basement Membrane/drug effects , Basement Membrane/virology , Body Fluids/drug effects , Body Fluids/virology , Cell Line , Glycosylation/drug effects , HEK293 Cells , Humans , Inflammation/drug therapy , Inflammation/virology , Influenza, Human/drug therapy , Influenza, Human/virology , Lung/drug effects , Lung/virology , Mice , Mice, Inbred C57BL , Orthomyxoviridae Infections/drug therapy , Orthomyxoviridae Infections/virology , Viral Load/methods
2.
Hum Mol Genet ; 25(7): 1357-69, 2016 Apr 01.
Article in English | MEDLINE | ID: mdl-26908621

ABSTRACT

Muscular dystrophy is characterized by progressive skeletal muscle weakness and dystrophic muscle exhibits degeneration and regeneration of muscle cells, inflammation and fibrosis. Skeletal muscle fibrosis is an excessive deposition of components of the extracellular matrix including an accumulation of Collagen VI. We hypothesized that a reduction of Collagen VI in a muscular dystrophy model that presents with fibrosis would result in reduced muscle pathology and improved muscle function. To test this hypothesis, we crossed γ-sarcoglycan-null mice, a model of limb-girdle muscular dystrophy type 2C, with a Col6a2-deficient mouse model. We found that the resulting γ-sarcoglycan-null/Col6a2Δex5 mice indeed exhibit reduced muscle pathology compared with γ-sarcoglycan-null mice. Specifically, fewer muscle fibers are degenerating, fiber size varies less, Evans blue dye uptake is reduced and serum creatine kinase levels are lower. Surprisingly, in spite of this reduction in muscle pathology, muscle function is not significantly improved. In fact, grip strength and maximum isometric tetanic force are even lower in γ-sarcoglycan-null/Col6a2Δex5 mice than in γ-sarcoglycan-null mice. In conclusion, our results reveal that Collagen VI-mediated fibrosis contributes to skeletal muscle pathology in γ-sarcoglycan-null mice. Importantly, however, our data also demonstrate that a reduction in skeletal muscle pathology does not necessarily lead to an improvement of skeletal muscle function, and this should be considered in future translational studies.


Subject(s)
Collagen Type VI/metabolism , Down-Regulation , Muscle, Skeletal/metabolism , Muscular Dystrophy, Animal/metabolism , Sarcoglycanopathies/metabolism , Animals , Mice , Mice, Knockout , Muscular Dystrophy, Animal/pathology , Muscular Dystrophy, Animal/physiopathology , Sarcoglycanopathies/pathology , Sarcoglycanopathies/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...